Nonmelanoma skin cancer (NMSC), the most common human cancer, occurs predominantly in elderly individuals. NMSCs include two main histological types, that is, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) ([@bib10]). Age-adjusted incidence rates of both BCC and SCC have been increasing during recent decades ([@bib10]). Some laboratory studies have demonstrated antineoplastic effect of statins against NMSC ([@bib3]; [@bib16]). However, the results of both laboratory and human studies are equivocal and two meta-analyses of statin use and risk of NMSC have given conflicting results. [@bib8] reported an increased risk for NMSC, whereas [@bib9] found a neutral effect. The conflicting evidence on statin use and NMSC risk prompted us to conduct a large nationwide study of statin use and risk of BCC or SCC.

Materials and methods
=====================

Our study was designed as a nested case--control study, based on information from nationwide Danish registries. The registries were linked by means of the civil registration number assigned to all Danish residents ([@bib11]). Danish citizens, who are mainly Caucasians, have equal tax-supported access to health care provided by the Danish National Health Service.

From the Danish Cancer Registry (DCR) ([@bib6]) we identified all individuals with a histologically verified first diagnosis of BCC or SCC between 1 January 2005 and 31 December 2009 and no prior cancer diagnosis. The date of diagnosis recorded in the DCR was defined as the index date.

For each case we randomly selected 10 age- and sex-matched population controls using risk-set sampling ([@bib12]; [@bib11]). We restricted the subjects to persons who had resided in Denmark for at least 10 consecutive years before the index date and excluded organ recipients.

We retrieved prescription data from 1995 (where nationwide recording of prescription use was initiated in the Prescription Registry) to 1 year before the index date for both cases and controls. Statin use was classified as ever use (⩾2 statin prescriptions; ATC group C10AA) or nonuse (0 or 1 statin prescription). We furthermore calculated the cumulative duration, cumulative amount, and intensity of statin use and classified statins by lipophilicity.

We used conditional logistic regression to compute crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for BCC or SCC associated with statin use. In all analyses, statin use was compared with nonuse. In the regression models, we included use of systemic glucocorticoids, azathioprine, other immunosuppressants, thiazides, other diuretics, hormone replacement therapy, amiodarone, low-dose aspirin, and nonaspirin nonsteroidal anti-inflammatory (NSAID) drugs. From the Danish patient register, we obtained information on history of chronic obstructive pulmonary disease (COPD) (as a proxy measure for heavy tobacco smoking), connective tissue disease, moderate to severe kidney disease, diabetes, psoriasis, and atopic dermatitis in the models. We classified subjects according to the Charlson comorbidity index (CCI) score ([@bib2]), and as a marker of socioeconomic status we included information on the highest educational level achieved by study subjects.

The online supplement provides further description of the utilised registries, definition of drug exposure and covariates, and supplementary analyses.

Results
=======

The study population is depicted in [Figure 1](#fig1){ref-type="fig"}. Compared with controls, cases of BCC had more years of schooling, lower prevalence of diabetes and COPD, lower CCI scores, and higher user prevalence of azathioprine, glucocorticoid, other immunosuppressants, and thiazides ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Squamous cell carcinoma cases had a higher prevalence of diabetes, psoriasis, atopic dermatitis, COPD, connective tissue disease, and kidney disease than their corresponding controls. A higher comorbidity among SCC cases was also reflected by higher CCI scores and higher use of most of the selected drugs ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Overall, 17.5% of BCC cases and 20.9% of SCC cases were ever users of statins compared with 17.2 and 19.4% among controls ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). This yielded adjusted ORs of 1.09 (95% CI: 1.06--1.13) and 1.01 (0.91--1.11), respectively, for the association between ever statin use and risk of BCC or SCC ([Table 1](#tbl1){ref-type="table"}). Analyses by duration of statin use and cumulative use yielded similar results as did restriction to study subjects with index dates during 2008--2009 with 10+ years of statin exposure.

We observed lower ORs for use of hydrophilic statins than for use of lipophilic statins, notably for SCC (lipophilic: OR 1.08, 95% CI: 0.89--1.30; hydrophilic OR 0.78, 95% CI: 0.40--1.51) ([Table 1](#tbl1){ref-type="table"}). Analyses by specific statin drugs yielded ORs around unity for the most frequently used statins, whereas elevated ORs were observed for less frequently used statins, for example, fluvastatin (BCC: OR, 1.59; 95% CI: 1.17--2.16). However, the OR estimates for the individual statins were based on small numbers.

Statin use was associated with slightly higher ORs for BCC and SCC in women compared with men ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In addition, study subjects \>75 years had slightly elevated ORs for both BCC and SCC with long-term use (⩾5 years) of statins ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Stratification by age and gender, respectively, yielded some variation in ORs but no clear patterns. The remaining supplementary analyses yielded results for BCC and SCC similar to those of the main analyses (data not shown).

Discussion
==========

In this large population-based study, we found no apparent association between long-term use of statins and risk of BCC or SCC. Furthermore, risk estimates for BCC or SCC did not differ materially according to duration, cumulated dose, or type of statin.

Few previous epidemiological studies have addressed the risk of NMSC associated with statin use. In a post-trial analysis of the Veterans Affairs Topical Tretinoin Chemoprevention trial ([@bib4]), no association was found in a propensity score-matched analyses of the study cohort (BCC: RR, 0.92; 95% CI: 0.73--1.16, SCC: RR, 0.88; 95% CI: 0.63--1.23). Another US study ([@bib1]) reported a neutral RR of 1.01 (95% CI: 0.92--1.12) for secondary BCC among patients with primary BCC, whereas long-term (\>5 years) statin use was associated with a slightly increased RR of 1.29 (95% CI: 0.93--1.81). In a large record-linkage study from Finland, long-term (\>5 years) statin use was associated with an increased risk of NMSC (RR, 1.33; 95% CI: 1.15--1.54), although tests for trend were significant only for pravastatin ([@bib7]). No disease-specific estimates were reported for BCC or SCC. Finally, two meta-analyses reported cumulative results on the risk of NMSC associated with statin use ([@bib8], [@bib9]). In the study by [@bib8] that included data only from RCTs of statin, the authors reported a 30--60% (depending on study selection) increased risk of NMSC among statin users. In a more recent meta-analysis, including data from both RCTs and observational studies, no apparent association was found between statin use and NMSC risk ([@bib9]). Thus, although methodological issues hamper straightforward comparisons, our finding of no apparent link between use of statin and risk of NMSC is in line with most previous studies.

Our study had a number of strengths. We used a nationwide prescription registry to assess statin use, an approach that provided detailed long-term drug use histories and eliminated recall bias. In Denmark, statins can only be obtained by prescription. Our use of nationwide registries with virtually complete coverage and continuously updated data on demographic characteristics, hospital contacts and cancer outcomes minimised selection bias. During the study period, the registration of NMSC in the DCR was based on reports from the primary health care sector and the patient register combined with diagnoses from the pathology registry, which holds records of all histological examinations of skin biopsies performed by private practitioners and at hospitals. This secured complete ascertainment of histologically verified NMSC cases and allowed evaluation of the association with statin use by histological type of NMSC.

Our study also had some potential limitations. First, we were not able to adjust for differences in sun habits. A high cumulated level of sunlight exposure is associated with an average 3.5-fold excess risk of SSC ([@bib5]). This level of sunlight exposure has been estimated to pertain to ∼25% of a Western population ([@bib5]). Using these figures combined with the exposure prevalence of 16% for statins in our study and the 'rule-out\' approach ([@bib13]), we estimated that even a statin--sunlight exposure association as low as 1.38 would fully explain an observed OR of 1.1 for statins and SCC. The slight increase in risk of NMSC associated with statin use observed in our study can therefore easily be explained by residual confounding by sunlight exposure or other unmeasured confounding. According to a recent Danish survey of 13 996 individuals, statin users had less healthy lifestyle profiles than nonusers of the drug; however, that study did not include data on sun light exposure ([@bib15]). Second, we cannot exclude some degree of socioeconomic confounding, although the study was conducted in a population with tax-supported free access to health care and, further, adjustment was performed for education in the analyses. A previous Danish survey reported a clear socioeconomic gradient in statin use among men but not women ([@bib14]); however, the gradient was markedly lower in the recent survey ([@bib15]).

In conclusion, our study does not indicate a major association between statin use and risk of BCC or SCC.
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![**Flow-chart of inclusion of cases of nonmelanoma skin cancer in Denmark 2005--2009.**](bjc2014527f1){#fig1}

###### Association between exposure to statins and nonmelanoma skin cancer

                                               **Basal cell carcinoma**   **Squamous cell carcinoma**          
  -------------------------------------------- -------------------------- ----------------------------- ------ -------------------
  Nonuse                                       31 740                     1.00 (ref)                    2946   1.00 (ref)
  Ever use                                     6152                       1.09 (1.06--1.13)             713    1.01 (0.91--1.11)
  **Duration of use, years**                                                                                   
  \<1                                          1863                       1.07 (1.02--1.13)             177    0.91 (0.77--1.08)
  ⩾1, \<3                                      2148                       1.06 (1.01--1.12)             268    1.08 (0.93--1.25)
  ⩾3, \<5                                      1315                       1.13 (1.06--1.20)             162    1.07 (0.89--1.29)
  ⩾5                                           1418                       1.11 (1.03--1.17)             171    1.02 (0.85--1.22)
  **Cumulative amount, DDD**                                                                                   
  \<200                                        1276                       1.11 (1.04--1.18)             116    0.91 (0.75--1.12)
  200--499                                     1352                       1.06 (1.00--1.13)             149    1.00 (0.83--1.20)
  500--999                                     1641                       1.09 (1.03--1.16)             209    1.11 (0.95--1.31)
  1000--1999                                   1634                       1.09 (1.03--1.16)             191    0.99 (0.84--1.18)
  ⩾2000                                        841                        1.07 (0.99--1.16)             113    1.06 (0.85--1.32)
  **Type of statin**                                                                                           
  Lipophilic                                   1242                       1.11 (1.04--1.18)             153    1.08 (0.89--1.30)
  Hydrophilic                                  82                         0.95 (0.75--1.20)             10     0.78 (0.40--1.51)
  **Intensity of treatment, DDD/year**                                                                         
  0--199                                       395                        1.18 (1.04--1.32)             49     1.09 (0.80--1.49)
  200--399                                     721                        1.09 (1.00--1.18)             78     0.96 (0.74--1.23)
  400+                                         302                        1.04 (0.92--1.18)             44     1.08 (0.77--1.51)
  **Statin drug[b](#t1-fn3){ref-type="fn"}**                                                                   
  Simvastatin                                  706                        1.10 (1.01--1.19)             91     1.05 (0.83--1.33)
  Lovastatin                                   49                         1.03 (0.76--1.38)             8      1.33 (0.62--2.84)
  Pravastatin                                  76                         0.93 (0.73--1.19)             10     0.80 (0.41--1.56)
  Fluvastatin                                  51                         1.59 (1.17--2.16)             3      0.59 (0.18--1.34)
  Atorvastatin                                 206                        1.03 (0.89--1.20)             22     0.85 (0.54--1.34)

Abbreviations: 95% CI=95% confidence interval; OR=odds ratio.

Adjusted for age, gender, years of schooling, history of atopic dermatitis, psoriasis, COPD, diabetes, CCI-score, and use of systemic glucocorticoids, azathioprine, other immunosuppressants, thiazides, other diuretics, hormone replacement therapy, amiodarone, low-dose aspirin, or non-aspirin NSAID drugs

Use for ⩾5 years versus nonuse; cerivastatin and rosuvastatin not presented owing to small numbers.
